Clinical trials: Intravitreal Injection
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration
This study will evaluate and compare two individualized ranibizumab treatment regimens in patients with neovascular (wet) AMD aiming to achieve and to maintain a maximum visual function benefit, while aiming to avoid unnecessary…
- Trial name
- OCTAVE (NCT01780935)
- Testing
- Ranibizumab
- Where
- 92 sites in Argentina, Austria and 22 more
- Volunteers
- 671 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
Study for Recalcitrant Age Related Macular Degeneration
50 Patients with recalcitrant exudative age-related macular degeneration with a history of retinal or subretinal fluid after multiple intravitreal injections with ranibizumab 0.5mg and subsequently treated with ranibizumab 2.0mg…
- Trial name
- TURF (NCT01543568)
- Testing
- aflibercept 2.0 mg
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- David M. Brown, M.D.
Choroid Neovascularization, Age-Related Macular Degeneration
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
- Trial name
- NCT00395057
- Testing
- AGN 211745, Ranibizumab 500µg
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 138 people
- Sponsor
- Allergan
Diabetic Macular Edema, Retinal Disease
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema.
- Conditions
- Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus
- Trial name
- NCT06011798
- Testing
- Aflibercept, foselutoclax
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Unity Biotechnology, Inc.
Uveitis, Intermediate Uveitis
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- NCT01789320
- Testing
- triamcinolone acetonide (Triesence®)
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Clearside Biomedical, Inc.
Uveal Melanoma
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma.
- Trial name
- NCT03712904
- Testing
- Stereotactic Body Radiation Therapy, Ziv-Aflibercept
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Neovascular Age-related Macular Degeneration
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.
- Trial name
- NCT05275205
- Testing
- UBX1325 injection 50 μL, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Unity Biotechnology, Inc.
Symptomatic Vitreomacular Adhesion
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.
- Trial name
- NCT01889251
- Testing
- Ocriplasmin
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Alcon Research
Diabetic Macular Edema
A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema
The purpose of this research study is to determine if a "Treat and Extend" regimen (increasing the time between visits when the disease is stable and not getting worse) of Ranibizumab 0.3 mg injections inside the eye is safe and…
- Trial name
- TREX-DME (NCT01934556)
- Testing
- Ranibizumab 0.3 mg intravitreal injection, Guided Laser Photocoagulation
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Palmetto Retina Center, LLC
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
This is a Phase 3, multicenter, randomized, masked, controlled, parallel group study of 12 months duration in treatment naïve subjects with RVO.
- Trial name
- SAPPHIRE (NCT02980874)
- Testing
- suprachoroidal CLS-TA, IVT aflibercept
- Where
- 110 sites in United States, Australia and 14 more
- Volunteers
- 460 people
- Sponsor
- Clearside Biomedical, Inc.
Age-related Macular Degeneration
RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
This is an open label, non-controlled, dose-escalating study assessing the safety, tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in approximately nine subjects with exudative age-related…
- Trial name
- SUSHI (NCT03633084)
- Testing
- RBM-007 Injectable Solution
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Ribomic USA Inc
Ocular Anesthesia
Cryoanesthesia for Intravitreal Injections
The cryoanesthesia (CA) device is designed to provide anesthesia to a focal area on the surface of the eye immediately prior to intraocular injections.
- Trial name
- NCT02872012
- Testing
- Cryoanesthesia device, Lidocaine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Retinal Vein Occlusion, Age Related Macular Degeneration
Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion…
- Trial name
- NCT02140411
- Testing
- Ranibizumab Intravitreal injections
- Where
- Chile
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Age - Related Macular Degeneration (AMD)
Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
This is a phase 4, open-label, single arm, multicenter, clinical study in patients with neovascular AMD designed to evaluate the efficacy and safety of Intravitreal Aflibercept Injection (IAI) administered over 2 years , and to…
- Trial name
- RE-VIEW (NCT01722045)
- Testing
- Intravitreal Aflibercept Injection (IAI)
- Where
- 49 sites in United States
- Volunteers
- 154 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KINGFISHER (NCT03917472)
- Testing
- Brolucizumab, Aflibercept
- Where
- 92 sites in United States, Hungary and 3 more
- Volunteers
- 517 people
- Sponsor
- Novartis Pharmaceuticals
Retinitis Pigmentosa (RP)
Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa
This study evaluates the safety and potential activity of a single dose of live human retinal progenitor cells (jCell) administered to adults with retinitis pigmentosa.
- Trial name
- NCT02320812
- Testing
- human retinal progenitor cells
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- jCyte, Inc
Diabetes Mellitus, Macular Edema
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular…
- Trial name
- VIVID-DME (NCT01331681)
- Testing
- VEGF Trap-Eye (BAY86-5321), Macular Laser Photocoagulation (Control)
- Where
- 73 sites in Australia, Austria and 9 more
- Volunteers
- 406 people
- Sponsor
- Bayer
Age-Related Macular Degeneration
Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy
This study will compare the safety and efficacy of Medidur FA treatment in one eye to the sham-treated fellow eye of subjects with geographic atrophy secondary to AMD.
- Trial name
- NCT00695318
- Testing
- Fluocinolone Acetonide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Alimera Sciences
Geographic Atrophy
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
- Trial name
- NCT03525600
- Testing
- APL-2
- Where
- 141 sites in United States, Argentina and 13 more
- Volunteers
- 621 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Neovascular Age-Related Macular Degeneration
Safety and Tolerability Study for Age-Related Macular Degeneration
Phase 1: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of hI-con1™ for subjects with Age-Related Macular Degeneration.
- Trial name
- NCT01485588
- Testing
- hI-con1™ 60µl, hI-con1™ 150µl, hI-con1™ 300µl
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Iconic Therapeutics, Inc.